Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.

Halper Sadeh encourages Mersana shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Mersana and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Mersana shareholders; (2) determine whether Day One is underpaying for Mersana; and (3) disclose all material information necessary for Mersana shareholders to adequately assess and value the merger consideration.

On behalf of Mersana shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251113493155/en/